p53 expression in normal, dysplastic, and neoplastic laryngeal epithelium. Absence of a correlation with prognostic factors

p53 expression has been examined in 89 squamous cell carcinomas of the larynx (34 glottic, 28 supraglottic, 18 transglottic, 8 pyriform sinus, and 1 subglottic) obtained from 88 patients surgically treated in our centre. In addition, 59 laryngeal samples including normal respiratory epithelium and non‐invasive squamous cell lesions were also tested. Frozen sections were immunostained with PAb 1801 and the results were correlated with pathological features, DNA ploidy and S‐phase of the tumours, disease‐free interval, and survival of the patients. p53 immunoreactivity was observed in 57 (64 per cent) carcinomas. None of the eight samples of normal respiratory epithelium was positive. p53‐positive cells were seen in 8 of 23 (35 per cent) squamous cell metaplasias, 6 of 19 (32 per cent) low‐grade dysplasias and 5 of 10 (50 per cent) high‐grade dysplasias. No correlation was found between p53 expression in carcinomas and their clinical and pathological characteristics, DNA ploidy, or proliferative activity. Neither disease‐free nor overall survival showed differences between p53‐positive and p53‐negative cases. These findings indicate that p53 may play a role in an early stage of malignant transformation of a subset of squamous cell carcinomas of the larynx, but seems not to be associated with further progression of the tumours.

[1]  H. Naiki,et al.  Over‐expression of p53 protein in human laryngeal carcinoma , 2009, International journal of cancer.

[2]  R. Metcalf,et al.  p53 protein accumulates frequently in early bronchial neoplasia. , 1993, Cancer research.

[3]  D. Spandidos,et al.  The role of the p53 tumor suppressor gene in squamous cell carcinoma of the head and neck. , 1993, Archives of otolaryngology--head & neck surgery.

[4]  F. Bosch,et al.  Expression of mutated p53 occurs in tumor-distant epithelia of head and neck cancer patients: a possible molecular basis for the development of multiple tumors. , 1993, Cancer research.

[5]  A. Malliri,et al.  P53 expression in end-stage squamous-cell carcinoma of the head and neck prior to chemotherapy treatment - expression correlates with a very poor clinical outcome. , 1993, International journal of oncology.

[6]  A. Cuschieri,et al.  Expression of P53 protein in normal, dysplastic, and malignant gastric mucosa: An immunohistochemical study , 1993, The Journal of pathology.

[7]  S. Qiu,et al.  Accumulation of p53 protein in human esophageal precancerous lesions: a possible early biomarker for carcinogenesis. , 1993, Cancer research.

[8]  W. Hong,et al.  Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract. , 1993, Cancer research.

[9]  T. Oyama,et al.  Overexpression of p53 as a Possible Prognostic Factor in Human Thyroid Carcinoma , 1993, The American journal of surgical pathology.

[10]  Brian H. Mayall,et al.  Guidelines for implementation of clinical DNA cytometry , 1993 .

[11]  B. Vogelstein,et al.  A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia , 1992, Cell.

[12]  R. Metcalf,et al.  p53 mutation and protein accumulation during multistage human esophageal carcinogenesis. , 1992, Cancer research.

[13]  D. Lane,et al.  The relationship of p53 immunostaining to survival in carcinoma of the lung. , 1992, British Journal of Cancer.

[14]  R. Maestro,et al.  p53 over‐expression is an early event in the development of human squamous‐cell carcinoma of the larynx: Genetic and prognostic implications , 1992, International journal of cancer.

[15]  D. Brachman,et al.  Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. , 1992, Cancer research.

[16]  Bert Vogelstein,et al.  p53 function and dysfunction , 1992, Cell.

[17]  T. Visakorpi,et al.  Association of overexpression of tumor suppressor protein p53 with rapid cell proliferation and poor prognosis in node-negative breast cancer patients. , 1992, Journal of the National Cancer Institute.

[18]  G. Wolf,et al.  DNA Content and histologic growth pattern correlate with prognosis in patients with advanced squamous cell carcinoma of the larynx , 1992 .

[19]  E. Kawasaki,et al.  Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. , 1992, Journal of the National Cancer Institute.

[20]  R. Maestro,et al.  High frequency of p53 gene alterations associated with protein overexpression in human squamous cell carcinoma of the larynx. , 1992, Oncogene.

[21]  D. Wynford‐Thomas.  P53 in tumour pathology: Can we trust immunocytochemistry? , 1992, The Journal of pathology.

[22]  T. Sugimura,et al.  Frequent association of p53 gene mutation in invasive bladder cancer. , 1992, Cancer research.

[23]  R. Metcalf,et al.  Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners , 1992, The Lancet.

[24]  S. Hirohashi,et al.  Aberrations of the tumor suppressor p53 and retinoblastoma genes in human hepatocellular carcinomas. , 1991, Cancer research.

[25]  R. Metcalf,et al.  Archival analysis of p53 genetic and protein alterations in Chinese esophageal cancer. , 1991, Oncogene.

[26]  A. Malliri,et al.  Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. , 1991, British Journal of Cancer.

[27]  E. Campo,et al.  Loss of heterozygosity of p53 gene and p53 protein expression in human colorectal carcinomas. , 1991, Cancer research.

[28]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[29]  Medicine,et al.  Overexpression and mutation of p53 in epithelial ovarian cancer. , 1991, Cancer research.

[30]  H. Mewes,et al.  p53 in colorectal cancer: clinicopathological correlation and prognostic significance , 1991, British Journal of Cancer.

[31]  J. Bartek,et al.  Patterns of expression of the p53 tumour suppressor in human breast tissues and tumours in situ and in vitro , 1990, International journal of cancer.

[32]  W. Bodmer,et al.  p53 mutations in colorectal cancer. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[33]  A. Harris,et al.  Increased expression of mutant forms of p53 oncogene in primary lung cancer , 1990, The Lancet.

[34]  D. Hedley.  Flow cytometry using paraffin-embedded tissue: five years on. , 1989, Cytometry.

[35]  F. Berrino,et al.  Cancer of the larynx/hypopharynx, tobacco and alcohol: Iarc international case‐control study in Turin and Varese (Italy), Zaragoza and Navarra (Spain), Geneva (Switzerland) and Calvados (France) , 1988, International journal of cancer.

[36]  A. Moreno,et al.  Prognostic factors in laryngeal carcinoma: A multifactorial study of 416 cases , 1986, Cancer.